Gt Biopharma Inc Stock Price, News & Analysis

GT Biopharma (NASDAQ: GTBP), a clinical stage immuno-oncology company, has announced the appointment of Andrew Ritter to its Board of Directors, replacing Dr. Rajesh Shrotriya. Ritter brings over 20 years of leadership experience in biotechnology and healthcare technology to GTBP's board.

Currently serving as CEO of Cairns Health, Ritter's track record includes successful leadership roles at Docbot and Ritter Pharmaceuticals. At Ritter Pharmaceuticals, which he founded and led for nearly 17 years, he guided the company through clinical trials and achieved a NASDAQ listing. He holds a B.A. from USC and an MBA from Wharton.

GT Biopharma (NASDAQ: GTBP), a clinical stage immuno-oncology company, has appointed Hilary Kramer to its Board of Directors, replacing Bruce Wendel. Kramer, the Founder and Chief Investment Officer of GreenTech Research, brings extensive experience in investment management and corporate governance. She previously served as Senior Managing Director and CIO for a $12 billion family office portfolio and held board positions at several public companies. Her background includes roles at Lehman Brothers, Morgan Stanley, and General Mills. Kramer holds a B.A. from Wellesley College and an MBA from Wharton School.

GT Biopharma (NASDAQ: GTBP) announced its participation in the 10th Anniversary of the Innate Killer Summit in San Diego from March 3-5, 2025. Dr. Jeffrey Miller from the University of Minnesota Medical School will present as an expert speaker, discussing tri-specific engagers' mechanisms in enhancing NK cell activity.

The company's second-generation TriKE®, GTB-3650, is currently in a Phase 1 dose escalation study for patients with hematological malignancies. The trial will evaluate:

• Up to 14 patients across seven cohorts
• Focus on relapsed or refractory CD33 expressing hematologic malignancies
• Including refractory acute myeloid leukemia (AML)
• High-risk myelodysplastic syndrome (MDS)

Enrollment is progressing as planned, with initial data expected in 2025. The trial is registered on clinicaltrials.gov under identifier NCT06594445.

GT Biopharma (NASDAQ: GTBP) has announced agreements for the exercise of existing warrants to purchase 302,069 shares of common stock. The warrants, originally issued in May 2024 with a $4.35 exercise price, will now be exercised at $2.27 per share, generating approximately $0.7 million in gross proceeds before fees.

In exchange for the immediate exercise, the company will issue new unregistered warrants to purchase 604,138 shares at $2.02 per share. Half of these new warrants have a five-year term, while the other half expire in eighteen months. The offering, with H.C. Wainwright & Co. as exclusive placement agent, is expected to close around February 27, 2025.

The proceeds will be used for working capital and general corporate purposes. The new warrants are being offered through private placement and the company will file a registration statement for the resale of shares issuable upon exercise.

GT Biopharma (NASDAQ: GTBP), a clinical stage immuno-oncology company developing therapeutics based on their proprietary TriKE® natural killer (NK) cell engager platform, has filed a Request for Withdrawal with the SEC regarding their Form S-1 Registration Statement (File No. 333-284032).

The Registration Statement, originally filed on December 23, 2024, had not been declared effective by the SEC, and no securities were sold in connection with the offering described in the document. The company clarified that this announcement does not constitute an offer to sell or solicitation to buy the Company's common stock or any securities.

GT Biopharma further emphasized that no offer, solicitation, or sale of securities mentioned would occur in any state or jurisdiction where such actions would be unlawful prior to proper registration or qualification under applicable securities laws.

GT Biopharma (NASDAQ: GTBP) has announced the dosing of its first patient in a Phase 1 trial of GTB-3650, its second-generation TriKE therapy, for treating relapsed or refractory CD33 expressing hematologic malignancies. The trial will evaluate up to 14 patients across seven cohorts, focusing on conditions including refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).

GTB-3650, utilizing camelid nanobody technology, will be administered in two-week blocks (two weeks on, two weeks off) for up to four months. The study aims to assess safety, pharmacokinetics, pharmacodynamics, NK cell expansion, and clinical activity. Initial data from this Phase 1 trial is expected in 2025.

GT Biopharma (NASDAQ: GTBP) reported Q3 2024 financial results with a net loss of $3.4 million, compared to $2.4 million in Q3 2023. The company maintains $6.5 million in cash, expected to fund operations into Q2 2025. R&D expenses remained flat at $1.3 million, while SG&A expenses increased to $2.3 million from $1.2 million year-over-year.

The company expects to dose its first patient in the GTB-3650 Phase 1 trial in Q4 2024, with initial clinical data expected in Q2 2025. Additionally, GTB-5550 IND submission for B7H3 positive solid tumors is planned for 1H 2025, with phase 1 trials expected to begin in 2025.

GT Biopharma (NASDAQ: GTBP) announced its participation in the 3rd Annual ROTH Healthcare Opportunities Conference on October 9, 2024, in New York, NY. Dr. Jeffrey Miller, GT Biopharma's Consulting Senior Medical Director, will join a panel discussion on innovative therapies for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

The panel, titled 'Focus: Hematologic malignancies', is scheduled for 1:15-1:55 pm ET. Dr. Miller, who is also the Deputy Director of the Masonic Cancer Center and Co-Leader of the Immunology Program at the University of Minnesota Medical School, will share insights on GT Biopharma's NK cell engager TriKE® platform.

Company management will be available for one-on-one meetings during the event. Interested parties can arrange meetings through their ROTH representatives.